Melatonin on the outcome of patients with Polycystic ovarian syndrome

Studying the effect of melatonin on the outcome of patients with Polycystic ovarian syndrome treated with intrauterine insemination

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250126064525N1

Enrollment

200

Registered

2025-01-29

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Administered 1 oral melatonin tablet, 5 mg, manufactured by Razak Company, once a day. Intervention 2: Control group: Administered 1 placebo tablet manufactured by

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Informed consent Polycystic ovarian syndrome

Exclusion criteria

Exclusion criteria: Underlying conditions such as diabetes and high blood pressure Melatonin allergy

Design outcomes

Primary

Measure	Time frame
Chemical pregnancy. Timepoint: Two weeks after insemination. Method of measurement: Bhcg blood level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Rafiei

Esfahan University of Medical Sciences

Samira_rafiei@gmail.com+98 31 3668 7898

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026